gatifloxacin has been researched along with Staphylococcal Infections in 30 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
Staphylococcal Infections: Infections with bacteria of the genus STAPHYLOCOCCUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of the present study was to evaluate the effectiveness of topically applied gemifloxacin for the treatment of experimental Staphylococcus aureus keratitis in a rabbit model." | 7.78 | Efficacy of gemifloxacin for the treatment of experimental Staphylococcus aureus keratitis. ( Chen, H; Jiang, H; Liu, T; Song, Z; Wu, X; Xu, Y; Yang, L; Yue, W, 2012) |
| "In the rabbit keratitis model, the ocular inflammation was significantly reduced by gatifloxacin as compared to levofloxacin but there was no significant difference between the groups in the number of viable bacteria." | 7.74 | Immunomodulatory effect of gatifloxacin on mouse peritoneal macrophages in vitro and in models of endotoxin-induced rat conjunctivitis and rabbit bacterial keratitis. ( Inoue, T; Kida, T; Naka, H; Sakaki, H; Tokushige, H; Wada, T, 2008) |
| "3% gatifloxacin drops to prevent endophthalmitis in a rabbit model." | 7.73 | Prevention of Staphylococcus aureus endophthalmitis with topical gatifloxacin in a rabbit prophylaxis model. ( Bartholomew, LR; de Castro, LE; Sandoval, HP; Solomon, KD; Vroman, DT, 2006) |
| "Osteomyelitis is an inflammatory bone disease caused by pyogenic bacteria." | 5.34 | Gatifloxacin biodegradable implant for treatment of experimental osteomyelitis: in vitro and in vivo evaluation. ( Baddour, MM; El-Kamel, AH, 2007) |
| "The objective of the present study was to evaluate the effectiveness of topically applied gemifloxacin for the treatment of experimental Staphylococcus aureus keratitis in a rabbit model." | 3.78 | Efficacy of gemifloxacin for the treatment of experimental Staphylococcus aureus keratitis. ( Chen, H; Jiang, H; Liu, T; Song, Z; Wu, X; Xu, Y; Yang, L; Yue, W, 2012) |
| "To compare pharmacodynamic indices and minimal inhibitory concentrations for vancomycin, gatifloxacin, moxifloxacin, linezolid, and combined quinupristin and dalfopristin for historic and current human coagulase-negative staphylococcus (CoNS) endophthalmitis isolates." | 3.74 | In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates. ( Flynn, HW; Harper, T; Miller, D, 2007) |
| "In the rabbit keratitis model, the ocular inflammation was significantly reduced by gatifloxacin as compared to levofloxacin but there was no significant difference between the groups in the number of viable bacteria." | 3.74 | Immunomodulatory effect of gatifloxacin on mouse peritoneal macrophages in vitro and in models of endotoxin-induced rat conjunctivitis and rabbit bacterial keratitis. ( Inoue, T; Kida, T; Naka, H; Sakaki, H; Tokushige, H; Wada, T, 2008) |
| "Topical therapy with gatifloxacin before and after intraocular bacteria challenge led to lower incidences of endophthalmitis in rabbits." | 3.74 | Prevention of endophthalmitis by collagen shields presoaked in fourth-generation fluoroquinolones versus by topical prophylaxis. ( Haugen, B; Haymore, J; Kleinmann, G; Mamalis, N; Olson, RJ; Romaniv, N; Werner, L, 2008) |
| "3% gatifloxacin drops to prevent endophthalmitis in a rabbit model." | 3.73 | Prevention of Staphylococcus aureus endophthalmitis with topical gatifloxacin in a rabbit prophylaxis model. ( Bartholomew, LR; de Castro, LE; Sandoval, HP; Solomon, KD; Vroman, DT, 2006) |
| "The fourth-generation fluoroquinolone, gatifloxacin, is an effective prophylaxis against the development of keratitis after lamellar keratectomy in rabbits with an organism resistant to methicillin, levofloxacin, and ciprofloxacin." | 3.72 | Fluoroquinolone therapy in multiple-drug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model. ( Carpenter, TR; Kaufman, MB; McDonnell, PJ; Sarayba, MA; Sweet, PM; Taban, M; Tungsiripat, T, 2003) |
| "The developed system is a viable alternative to conventional eyedrops of GTN due to its ability to enhance bioavailability through its longer precorneal residence time." | 1.43 | Therapeutic Effectiveness in the Treatment of Experimental Bacterial Keratitis with Ion-activated Mucoadhesive Hydrogel. ( Kant, S; Kesavan, K; Pandit, JK, 2016) |
| "Besifloxacin had an 8-fold lower MIC for MRSA than gatifloxacin and moxifloxacin, and was significantly more effective than gatifloxacin and moxifloxacin in reducing the number of MRSA in the rabbit cornea." | 1.36 | Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis. ( Marquart, ME; Moore, QC; Norcross, EW; Sanders, ME; Shafiee, A, 2010) |
| "Besifloxacin had an 8-fold lower MIC for MRSA than gatifloxacin and moxifloxacin and was significantly more effective than gatifloxacin and moxifloxacin in reducing the number of MRSA in the rabbit cornea 16 hours after infection." | 1.35 | Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis. ( Marquart, ME; Moore, QC; Norcross, EW; Sanders, ME; Shafiee, A, 2009) |
| "Bacterial endophthalmitis is a potential complication of ICL implantation." | 1.35 | Culture-positive endophthalmitis after implantation of intraocular Collamer lens. ( Cohen, JA; Davis, MJ; Dennis, RF; Epstein, RJ, 2009) |
| "Use the ID(50) (infectious dose to 50% of experimental animals) to quantify the most effective prophylactic dosing regimen to use with gatifloxacin 0." | 1.34 | Prophylactic gatifloxacin therapy in prevention of bacterial keratitis in a rabbit laser in situ keratomileusis model. ( Friday, JW; Kleinert, LB; Nix, DE; Patula, VB; Slade, DS; Snyder, RW, 2007) |
| "Osteomyelitis is an inflammatory bone disease caused by pyogenic bacteria." | 1.34 | Gatifloxacin biodegradable implant for treatment of experimental osteomyelitis: in vitro and in vivo evaluation. ( Baddour, MM; El-Kamel, AH, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (60.00) | 29.6817 |
| 2010's | 11 (36.67) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| de Souza, NJ | 1 |
| Gupte, SV | 1 |
| Deshpande, PK | 1 |
| Desai, VN | 1 |
| Bhawsar, SB | 1 |
| Yeole, RD | 1 |
| Shukla, MC | 1 |
| Strahilevitz, J | 1 |
| Hooper, DC | 1 |
| Bozdogan, B | 1 |
| Appelbaum, PC | 1 |
| Jacobs, MR | 1 |
| Shetty, N | 1 |
| Patel, MV | 1 |
| Jha, R | 1 |
| Khorakiwala, HF | 1 |
| Li, C | 1 |
| Liu, JC | 1 |
| Li, YR | 1 |
| Gou, C | 1 |
| Zhang, ML | 1 |
| Liu, HY | 1 |
| Li, XZ | 1 |
| Zheng, CJ | 1 |
| Piao, HR | 1 |
| Lin, S | 1 |
| Koh, JJ | 1 |
| Aung, TT | 1 |
| Lim, F | 1 |
| Li, J | 1 |
| Zou, H | 1 |
| Wang, L | 1 |
| Lakshminarayanan, R | 1 |
| Verma, C | 1 |
| Wang, Y | 1 |
| Tan, DT | 1 |
| Cao, D | 1 |
| Beuerman, RW | 1 |
| Ren, L | 1 |
| Liu, S | 1 |
| Bhawsar, S | 1 |
| Joshi, S | 1 |
| Deshpande, P | 1 |
| Yeole, R | 1 |
| Bhagwat, S | 1 |
| Patel, M | 1 |
| Coburn, PS | 1 |
| Miller, FC | 1 |
| LaGrow, AL | 1 |
| Land, C | 1 |
| Mursalin, H | 1 |
| Livingston, E | 1 |
| Amayem, O | 1 |
| Chen, Y | 1 |
| Gao, W | 1 |
| Zhang, L | 1 |
| Callegan, MC | 1 |
| Kesavan, K | 1 |
| Kant, S | 1 |
| Pandit, JK | 1 |
| Romanowski, EG | 2 |
| Mah, FS | 2 |
| Kowalski, RP | 2 |
| Yates, KA | 2 |
| Gordon, YJ | 2 |
| Hidalgo, M | 1 |
| Reyes, J | 1 |
| Cárdenas, AM | 1 |
| Díaz, L | 1 |
| Rincón, S | 1 |
| Vanegas, N | 1 |
| Díaz, PL | 1 |
| Castañeda, E | 1 |
| Arias, CA | 1 |
| O'Callaghan, R | 1 |
| Ohnsman, C | 1 |
| Song, J | 1 |
| Knobloch, JK | 1 |
| Von Osten, H | 1 |
| Horstkotte, MA | 1 |
| Rohde, H | 1 |
| Mack, D | 1 |
| Sanders, ME | 2 |
| Norcross, EW | 2 |
| Moore, QC | 2 |
| Shafiee, A | 2 |
| Marquart, ME | 2 |
| Davis, MJ | 1 |
| Epstein, RJ | 1 |
| Dennis, RF | 1 |
| Cohen, JA | 1 |
| Balzli, CL | 2 |
| McCormick, CC | 2 |
| Caballero, AR | 2 |
| O'Callaghan, RJ | 2 |
| Proksch, JW | 1 |
| Ward, KW | 1 |
| Kim, SJ | 1 |
| Toma, HS | 1 |
| Fintelmann, RE | 1 |
| Hoskins, EN | 1 |
| Lietman, TM | 1 |
| Keenan, JD | 1 |
| Gaynor, BD | 1 |
| Cevallos, V | 1 |
| Acharya, NR | 1 |
| Wu, X | 1 |
| Jiang, H | 1 |
| Xu, Y | 1 |
| Yue, W | 1 |
| Yang, L | 1 |
| Song, Z | 1 |
| Chen, H | 1 |
| Liu, T | 1 |
| Juárez-Verdayes, MA | 1 |
| Parra-Ortega, B | 1 |
| Hernández-Rodríguez, C | 1 |
| Betanzos-Cabrera, G | 1 |
| Rodríguez-Martínez, S | 1 |
| Cancino-Diaz, ME | 1 |
| Cancino-Diaz, JC | 1 |
| Tungsiripat, T | 1 |
| Sarayba, MA | 1 |
| Kaufman, MB | 1 |
| Sweet, PM | 1 |
| Taban, M | 1 |
| Carpenter, TR | 1 |
| McDonnell, PJ | 1 |
| Ambrose, PG | 1 |
| Anon, JB | 1 |
| Owen, JS | 1 |
| Van Wart, S | 1 |
| McPhee, ME | 1 |
| Bhavnani, SM | 1 |
| Piedmonte, M | 1 |
| Jones, RN | 1 |
| Moshirfar, M | 1 |
| Mirzaian, G | 1 |
| Feiz, V | 1 |
| Kang, PC | 1 |
| de Castro, LE | 1 |
| Sandoval, HP | 1 |
| Bartholomew, LR | 1 |
| Vroman, DT | 1 |
| Solomon, KD | 1 |
| Harper, T | 1 |
| Miller, D | 1 |
| Flynn, HW | 1 |
| Slade, DS | 1 |
| Friday, JW | 1 |
| Snyder, RW | 1 |
| Nix, DE | 1 |
| Kleinert, LB | 1 |
| Patula, VB | 1 |
| El-Kamel, AH | 1 |
| Baddour, MM | 1 |
| Wada, T | 1 |
| Kida, T | 1 |
| Inoue, T | 1 |
| Tokushige, H | 1 |
| Naka, H | 1 |
| Sakaki, H | 1 |
| Huang, B | 1 |
| Wigington, L | 1 |
| Smith, E | 1 |
| Tang, A | 1 |
| Haugen, B | 1 |
| Werner, L | 1 |
| Romaniv, N | 1 |
| Haymore, J | 1 |
| Kleinmann, G | 1 |
| Mamalis, N | 1 |
| Olson, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Conjunctival Floral Resistance in a Single Practice Site Comparing Povidone- Iodine Prep With or Without Post-Intravitreal Injection Second Generation Fluoroquinolones.[NCT02223338] | 120 participants (Actual) | Interventional | 2014-10-31 | Completed | |||
| An Open-Label Noncomparative, Multicenter, Clinical Trail Measuring Time Related Clinical Response Factors in Relation to Time to Bacterial Eradication With Tigecycline Treatment in Patients With Catheter Infection[NCT00419991] | Phase 4 | 10 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Average number of antibiotics to which isolated organisms were resistant, isolated organisms include only coagulase negative Staphylococcus species and Staphylococcus aureus. Antibiotics are those described in the methods section. (NCT02223338)
Timeframe: Through study completion, average of 4 weeks
| Intervention | antibiotics (Mean) |
|---|---|
| Ciprofloxacin | 5.44 |
| Standard Aseptic Technique | 3.23 |
"Resistance of all coagulase negative staph and staph aureus species to a panel of commonly used antibiotics will be determined and compared between groups. Resistance will be measured using minimum inhibitory concentrations which will be tested on the Siemens MicroScan instrument by doubling broth dilutions. Antibiotic susceptibility interpretations using the categories S for susceptible, I for Intermediate and R for Resistance based on the Clinical and Laboratory Standards Institute (CLSI) guidelines.~Ciprofloxacin will be tested using the Biomerieux E test strip. The test directly quantifies antimicrobial susceptibility in terms of discrete MIC values on a continuous gradient strip. The MIC values are also based on the CLSI guidelines giving interpretations of S, I or R.~For information on other antibiotics to be tested, please contact the investigator or provide more characters for input." (NCT02223338)
Timeframe: Cultured organisms will be subjected to resistance panels once they have grown and been identified. Cultures will be followed for 7 days total, and if no growth is recorded at that time they will be considered sterile.
| Intervention | Participants (Count of Participants) |
|---|---|
| Ciprofloxacin | 10 |
| Standard Aseptic Technique | 6 |
2 trials available for gatifloxacin and Staphylococcal Infections
| Article | Year |
|---|---|
Ophthalmic antibiotics and antimicrobial resistance a randomized, controlled study of patients undergoing intravitreal injections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Azithromycin; Conjunctiva; Dru | 2011 |
Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis.
Topics: Acute Disease; Anti-Bacterial Agents; Coagulase; Enterobacter aerogenes; Enterobacteriaceae Infectio | 2004 |
28 other studies available for gatifloxacin and Staphylococcal Infections
| Article | Year |
|---|---|
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Clinical Trials, Phase I as Topic; Dogs; Drug Resi | 2005 |
Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
Topics: Anti-Infective Agents; Candida albicans; Candidiasis; Escherichia coli; Escherichia coli Infections; | 2015 |
Symmetrically Substituted Xanthone Amphiphiles Combat Gram-Positive Bacterial Resistance with Enhanced Membrane Selectivity.
Topics: Animals; Anti-Bacterial Agents; Cornea; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Pos | 2017 |
WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Fluoroquinolones; Humans; Microbial Sensiti | 2022 |
Disarming Pore-Forming Toxins with Biomimetic Nanosponges in Intraocular Infections.
Topics: Animals; Bacterial Toxins; Biomimetic Materials; Erythrocytes; Eye Infections, Bacterial; Gatifloxac | 2019 |
Therapeutic Effectiveness in the Treatment of Experimental Bacterial Keratitis with Ion-activated Mucoadhesive Hydrogel.
Topics: Alginates; Animals; Anti-Bacterial Agents; Biological Availability; Carboxymethylcellulose Sodium; C | 2016 |
Benzalkonium chloride enhances the antibacterial efficacy of gatifloxacin in an experimental rabbit model of intrastromal keratitis.
Topics: Animals; Anti-Bacterial Agents; Benzalkonium Compounds; Corneal Stroma; Disease Models, Animal; Drug | 2008 |
[Resistance profiles to fluoroquinolones in clinical isolates of Gram positive cocci].
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Colombia; Dose-Response Relationship, Drug; Dru | 2008 |
Laboratory data and statistical evidence in fluoroquinolone study.
Topics: Administration, Topical; Animals; Anterior Chamber; Anti-Infective Agents; Collagen; Colony Count, M | 2008 |
Biofilm formation is not necessary for development of quinolone-resistant "persister" cells in an attached Staphylococcus epidermidis population.
Topics: Anti-Infective Agents; Aza Compounds; Bacterial Adhesion; Biofilms; Ciprofloxacin; Colony Count, Mic | 2008 |
Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Micr | 2009 |
Culture-positive endophthalmitis after implantation of intraocular Collamer lens.
Topics: Adult; Anti-Bacterial Agents; Drug Therapy, Combination; Endophthalmitis; Eye Infections, Bacterial; | 2009 |
Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Micr | 2010 |
Sustained anti-staphylococcal effect of lysostaphin in the rabbit aqueous humor.
Topics: Animals; Anti-Infective Agents; Anti-Infective Agents, Local; Aqueous Humor; Blotting, Western; Fluo | 2010 |
Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.
Topics: Administration, Topical; Animals; Aqueous Humor; Area Under Curve; Aza Compounds; Azepines; Conjunct | 2010 |
Topical fluoroquinolone use as a risk factor for in vitro fluoroquinolone resistance in ocular cultures.
Topics: Administration, Topical; Aged; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Disk Diffusion A | 2011 |
Efficacy of gemifloxacin for the treatment of experimental Staphylococcus aureus keratitis.
Topics: Animals; Anti-Infective Agents, Local; Colony Count, Microbial; Conjunctival Diseases; Cornea; Eye; | 2012 |
Identification and expression of nor efflux family genes in Staphylococcus epidermidis that act against gatifloxacin.
Topics: Anti-Bacterial Agents; DNA, Bacterial; Drug Resistance, Bacterial; Eye Infections; Fluoroquinolones; | 2012 |
Fluoroquinolone therapy in multiple-drug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Disease Mode | 2003 |
The successful treatment of gatifloxacin-resistant Staphylococcus aureus keratitis with Zymar (gatifloxacin 0.3%) in a NZW rabbit model.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents, Local; Cefazolin; Corneal Ulcer; Disease Mode | 2005 |
Fourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgery.
Topics: Adult; Aza Compounds; Bacteria; Cornea; Corneal Ulcer; Drug Resistance, Bacterial; Drug Therapy, Com | 2006 |
Prevention of Staphylococcus aureus endophthalmitis with topical gatifloxacin in a rabbit prophylaxis model.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Disease Models, Ani | 2006 |
In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates.
Topics: Acetamides; Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Aqueous Humor; Aza | 2007 |
Prophylactic gatifloxacin therapy in prevention of bacterial keratitis in a rabbit laser in situ keratomileusis model.
Topics: Animals; Anti-Infective Agents; Antibiotic Prophylaxis; Colony Count, Microbial; Corneal Ulcer; Dise | 2007 |
Gatifloxacin biodegradable implant for treatment of experimental osteomyelitis: in vitro and in vivo evaluation.
Topics: Absorbable Implants; Animals; Anti-Infective Agents; Disease Models, Animal; Drug Carriers; Female; | 2007 |
Immunomodulatory effect of gatifloxacin on mouse peritoneal macrophages in vitro and in models of endotoxin-induced rat conjunctivitis and rabbit bacterial keratitis.
Topics: Animals; Anti-Inflammatory Agents; Aza Compounds; Cells, Cultured; Conjunctivitis; Endotoxins; Fluor | 2008 |
Fluoroquinolone therapy in a rabbit model of post-LASIK methicillin-resistant Staphylococcus aureus keratitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Corneal Stroma; Corneal Ulce | 2008 |
Prevention of endophthalmitis by collagen shields presoaked in fourth-generation fluoroquinolones versus by topical prophylaxis.
Topics: Administration, Topical; Animals; Anterior Chamber; Anti-Infective Agents; Collagen; Colony Count, M | 2008 |